Pretesting cervical tumors could inform treatment

May 31, 2013 by Julia Evangelou Strait, Washington University School of Medicine in St. Louis
Pretesting cervical tumors could inform treatment
Before treatment, left, a cervical tumor is visible (white arrow) on a PET/CT scan. After successful treatment, right, the tumor is no longer visible. For reasons that are not well understood, some patients’ tumors do not respond to therapy. Testing the tumor before treatment for vulnerability to chemotherapy predicts which patients will do well or poorly with standard treatment. Credit: JULIE K. SCHWARZ, MD, PHD

(Medical Xpress)—Doctors at Washington University School of Medicine in St. Louis have shown that testing cervical tumors before treatment for vulnerability to chemotherapy predicts whether patients will do well or poorly with standard treatment. The study supports the future possibility of personalized medicine for cervical cancer, a tumor normally addressed with a one-size-fits-all approach.

"Even though this is a small study, its strength is that it links a lab test of the tumor's response to for the patients," said Julie K. Schwarz, MD, PhD, assistant professor of radiation oncology. "Very few cancers have been studied this way, and this is the first such report for cervical cancer."

Since 1999, nearly all cervical cancer cases have been treated the same way: daily targeted to the tumor plus a weekly intravenous infusion of the chemotherapy .

"We believe that radiation does the majority of the work with cervical cancer," said Schwarz, who treats patients at Siteman at Barnes-Jewish Hospital and Washington University School of Medicine. "But a published in 1999 showed that combining it with cisplatin chemotherapy improved survival outcomes."

Even today, according to Schwarz, doctors have no way of knowing who will do well or poorly with the combined radiation and chemotherapy that every patient receives. Now, Schwarz and her colleagues have shown that the tumor's response to chemotherapy, independent of radiation, may be a major deciding factor in whether a patient will do well with the standard treatment.

The study appears online in the journal Gynecologic Oncology.

"This is evidence that cisplatin is not just helping the radiation work better," Schwarz said. "It is having some direct on cancer cells that may be hiding elsewhere in the body, some place where the radiation is not hitting it, since we target the radiation so precisely to the main tumor. We think it would be beneficial for that drug to be selected appropriately for the patient's individual tumor."

The investigators tested tumors from 33 patients before their treatment began. They divided the patients' tumors into three categories – responsive, intermediate response and nonresponsive – based on how well cisplatin killed the tumor cells growing in a dish.

For tumors categorized as responsive – those that killed most easily – 100 percent of the patients were alive and disease-free after two years. For those that showed an intermediate response, 83 percent of the patients were alive and disease-free after two years. And for those tumors deemed nonresponsive, only 58 percent of patients had two-year disease-free survival.

Cervical cancers can be divided into two main types based on how they look under a microscope – squamous cell carcinoma and adenocarcinoma. The nonresponsive number was even worse for patients diagnosed with the more common squamous cell carcinoma, with 46 percent disease-free survival at two years.

"Ideally, we would like to be able to design clinical trials for the nonresponsive patients," Schwarz said. "One chemotherapy drug isn't working for everyone, but there isn't going to be one explanation for why the chemo doesn't work. It's going to be 50 different explanations, and figuring that out is the challenge."

Schwarz is quick to point out the weaknesses of this study. In addition to the small number of patients, the lab test used was not ideal and should not be used to decide therapy for patients, she said. The investigators initially evaluated 75 tumors for chemotherapy response. And though some patients' data was not included because they did not adhere to the treatment regimen, 31 patients were excluded from the analysis because their tumor cells did not grow well in the lab.

"This is definitely not the definitive test," Schwarz said. "But I think our results should prompt investigators to think outside the box and start generating new ideas about how best to treat this disease. The bottom line is a one-size-fits-all treatment for each patient is going by the wayside. As we develop personalized strategies, this is the sort of testing that can guide it."

Explore further: Radiation plus chemotherapy provides long-term positive results for head and neck cancer patients

More information: Grigsby PW, Zighelboim I, Powell MA, Mutch DG, Schwarz JK. In vitro chemoresponse to cisplatin and outcomes in cervical cancer. Gynecologic Oncology. Published online before print April 13, 2013. doi: 10.1016/j.ygyno.2013.04.005

Related Stories

Radiation plus chemotherapy provides long-term positive results for head and neck cancer patients

January 26, 2012
A select subgroup of advanced head and neck cancer patients treated with radiation therapy plus the chemotherapy drug cisplatin had more positive outcomes than patients treated with radiation therapy alone and continued to ...

Comparing combination therapies for advanced head and neck cancer shows no improvement

March 7, 2013
Locally advanced squamous cell carcinoma of the head and neck is a potentially curable disease in nearly every patient at the time of diagnosis, yet despite the most aggressive efforts, up to 30-50 percent of patients may ...

Cisplatin-resistant cancer cells sensitive to experimental anticancer drugs, PARP inhibitors

April 3, 2013
Poly (ADP-ribose) polymerase inhibitors may be a novel treatment strategy for patients with cancer that has become resistant to the commonly used chemotherapy drug cisplatin, according to data from a preclinical study published ...

Cervical cancer patients more likely to survive if treated at high-volume medical facilities

March 12, 2013
Patients with locally advanced cervical cancer have better treatment outcomes and are more likely to survive the disease if they receive care at a high-volume medical center than patients treated at low-volume facilities, ...

Genetic diversity within tumors predicts outcome in head and neck cancer

May 20, 2013
A new measure of the heterogeneity – the variety of genetic mutations – of cells within a tumor appears to predict treatment outcomes of patients with the most common type of head and neck cancer. In the May 20 issue ...

Recommended for you

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.